Question Title

* 1. Email address:

Question Title

* 2. Contact Information:

Question Title

* 3. Do you use gene-edited iPS cells in your research?

Question Title

* 4. If yes, in what application would you be using the gene-edited iPS cells? (Choose one option)

Question Title

* 5. What genetic change are you interested in introducing in iPS cells? (Choose max two options)

Question Title

* 6. How did you/are you planning to source custom gene-edited iPS cells?

Question Title

* 7. If you did/will do gene-editing yourself, what are the biggest challenges that you have faced so far?

Question Title

* 8. If you ordered/will order custom gene-edited iPS cell lines from an external vendor, what is important to you when you choose the vendor? (Choose max two options)

Question Title

* 9. If you wanted to outsource gene-editing of iPS cells, would you prefer final deliverable to be

Question Title

* 10. If you are interested in fully differentiated cells, what cell type(s) are you interested in?

Question Title

* 11. Knockout gene-editing project by introducing frameshift mutations into both alleles includes
  • Full characterization and optimization of cell line and reagent design
  • One round of targeting including screening of up to 100 clones
  • Genetic validation on gDNA level and alkaline phosphatase staining for assessment of pluripotency
  • Delivery of at least one clone (2 vials/clone)

Question Title

* 12. I would like to participate in the prize draw

                           

 

Terms and conditions

Only participants who have answered all the questions by 31 August 2016 will participate in a prize draw.

Participants working for a company providing gene-editing services on a commercial basis are not eligible for the survey.

The knockout gene-editing project will be performed in an iPSC line provided by the customer.

The project will not be initiated before the iPSC provided have been certified to be mycoplasma-free.

The knockout will be achieved by introducing frameshift mutations resulting from NHEJ into both alleles.  The project includes the following: Full characterization and optimization of cell line, reagent design (screening of 5 sgRNAs), one round of targeting including screening of up to 100 clones, genetic validation on gDNA level, mycoplasma Hoechst and culture isolation testing and alkaline phosphatase staining for assessment of pluripotency.

Knockout project will include one targeting event. Horizon Discovery will use its best efforts to deliver the desired genotype, however we cannot guarantee delivery for the cell line. Note that targeting phase will not be repeated in case the requested genetic modification is lethal or desired genotype has not been recovered during the first round of targeting.

The cell line is for internal R&D use only. For clarity, the commercial use is specifically excluded.

T